Group 1 - The Annual General Meeting (AGM) of Alvotech is scheduled for June 25, 2025, at 09:00 a.m. CEST [1] - The meeting will take place at the premises of Arendt & Medernach in Luxembourg [1] - Additional information and meeting materials are available on the Alvotech website [1]

Group 1: Company Overview - Alvotech is a biotech company focused on the development and manufacture of biosimilar medicines for patients worldwide [3] - The company aims to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services [3] - Alvotech has two approved biosimilars, Humira® (adalimumab) and Stelara® (ustekinumab), marketed in multiple global markets [3] - The current development pipeline includes nine disclosed biosimilar candidates targeting various diseases, including autoimmune disorders and cancer [3] Group 2: Strategic Partnerships - Alvotech has formed a network of strategic commercial partnerships to enhance its global reach and leverage local expertise [3] - Key commercial partners include Teva Pharmaceuticals, STADA Arzneimittel AG, and Fuji Pharma Co., Ltd., among others, covering various territories [3] - Each partnership is tailored to specific products and regions, enhancing Alvotech's market presence [3] Group 3: Liquidity Provider Agreement - Alvotech has entered into an agreement with DNB Carnegie Investment Bank AB for liquidity provider services for its Swedish Depository Receipts (SDRs) [1] - DNB Carnegie will continuously quote prices for Alvotech's SDRs to ensure liquidity and reduce the spread between buying and selling prices [2] - The liquidity provider arrangement is set to commence on May 20, 2025 [2]

Core Viewpoint - Alvotech has successfully completed its offering of Swedish Depository Receipts (SDRs) and is now listed on Nasdaq Stockholm, which is expected to enhance its visibility and access to capital in the Nordic and European markets [2][4][6]. Offering Details - The offering was oversubscribed multiple times, with a total of 441,600 SDRs issued at a price of SEK 87.51, resulting in gross proceeds of approximately SEK 39 million [8]. - The application period for the offering was from May 9 to May 16, 2025, and trading commenced on May 19, 2025, under the ticker "ALVO SDB" [8]. Strategic Expansion - Alvotech aims to expand its R&D capabilities by acquiring Xbrane Biopharma AB's R&D operations in Sweden, which will enhance its scientific and innovation capabilities [5]. - The integration of Xbrane's workforce is expected to strengthen Alvotech's presence in the Swedish life-science sector and support its growth trajectory [5]. Market Positioning - The listing on Nasdaq Stockholm is anticipated to improve access to regional capital and attract a broader base of institutional and retail investors [6]. - Alvotech is focused on becoming a global leader in biosimilars, with a current pipeline that includes nine disclosed biosimilar candidates targeting various diseases [11]. Shareholder Engagement - The company will offer a free conversion period for existing shareholders to convert their shares into SDRs, with Alvotech covering the conversion fees for one year [9].

Core Viewpoint - Alvotech, a global biotech company focused on biosimilar medicines, successfully completed an oversubscribed offering of Swedish Depository Receipts (SDRs) in connection with its listing on Nasdaq Stockholm, which is expected to enhance its market presence and access to capital [2][5][8]. Offering Details - The offering attracted strong interest, resulting in over 3,000 new shareholders and was multiple times oversubscribed [2][8]. - The final price per SDR was set at SEK 87.51, reflecting a 10% discount from the volume-weighted average price of the ordinary shares during the application period [8]. - The gross proceeds from the offering amounted to approximately SEK 39 million [8]. Strategic Expansion - Alvotech aims to expand its R&D capabilities, having recently acquired Xbrane Biopharma AB's R&D operations in Sweden, which will enhance its scientific and innovation capabilities [4]. - The integration of Xbrane's workforce is expected to strengthen Alvotech's presence in the Swedish life-science sector and support its growth trajectory [4]. Market Positioning - The listing on Nasdaq Stockholm is anticipated to improve Alvotech's recognition in Nordic and European markets, attracting a broader base of institutional and retail investors [5]. - There is strong investor demand for opportunities in European biotech, biopharma, and biosimilar stocks among Nordic and international institutional investors [5]. Trading Information - Trading of the SDRs on Nasdaq Stockholm is set to commence on May 19, 2025, under the ticker symbol "ALVO SDB" [8]. - A free conversion period for existing shareholders to convert their shares into SDRs will be offered for one year from the first trading day [7].

Alvotech (ALVO) Conference Call Summary Company Overview - Alvotech is a dedicated biosimilar company with a comprehensive pipeline and a focus on providing affordable biologic drugs globally, operating in over 90 countries [5][6][4]. Key Points and Arguments Business Model and Strategy - Alvotech has adopted a partnership model to maintain flexibility and expand its pipeline, which has led to the largest biosimilars pipeline in the industry with around 30 projects [5][6][7]. - The company specializes in both development and manufacturing of biosimilars, allowing for faster and more efficient execution compared to competitors who may rely on contract manufacturers [10][8][9]. - Vertical integration is not currently a focus, as the partnership model has proven successful [11]. Market Dynamics and Product Launches - The total addressable market and competitive landscape are critical factors in determining which products to pursue [13][15]. - Alvotech anticipates a steady stream of product launches, with six products expected by early next year and three to four more by the end of Q4 [18][19]. - The company expects to navigate pricing pressures through a broad pipeline and significant revenue from ex-U.S. markets [19][52]. Financial Projections - By 2028, Alvotech targets revenues of approximately $1.5 billion, with an EBITDA margin of 40% to 45% and product margins of 60% to 65% [24][25][56]. - The company has a CapEx requirement of $60 to $70 million for the year, with no substantial increases expected, indicating strong operating leverage as more products are commercialized [56][57]. Competitive Landscape - Alvotech differentiates itself through its proprietary auto-injector design and a focus on difficult-to-develop products, which allows it to leverage its R&D expertise [22]. - The company acknowledges the competitive dynamics in the U.S. market, particularly with the launch of biosimilars like Stellara, and expects a gradual ramp-up in market share [30][40]. Pricing and Market Adoption - Alvotech is cautious about entering a "race to the bottom" in pricing, emphasizing the importance of sustainable pricing strategies [45]. - The company has observed that European markets have become increasingly profitable and stable, contrary to previous perceptions that U.S. markets were more lucrative [47][48]. Partnerships and Collaborations - Alvotech has established strong partnerships with companies like Teva and Dr. Reddy's, which have been beneficial for regulatory approvals and market penetration [75]. Additional Important Insights - The company is prepared for potential FDA inspection issues with contingency plans and multiple partnerships in place [62]. - Alvotech is optimistic about the adoption of biosimilars in the ophthalmology market, particularly with products like EYLEA, and is positioned to launch competitively [63][71]. This summary encapsulates the key insights from the Alvotech conference call, highlighting the company's strategic focus, market dynamics, financial outlook, and competitive positioning in the biosimilars industry.

Company Overview - Alvotech is a global biotech company focused on the development and manufacture of biosimilar medicines for patients worldwide [3] - The company aims to be a leader in the biosimilar space by delivering high-quality, cost-effective products and services through a fully integrated approach and broad in-house capabilities [3] - Alvotech has launched two biosimilars and has a development pipeline that includes candidates for treating autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [3] Strategic Partnerships - Alvotech has formed a network of strategic commercial partnerships to enhance its global reach and leverage local expertise in various markets, including the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East [3] - Notable commercial partners include Teva Pharmaceuticals, STADA Arzneimittel AG, Fuji Pharma Co., Ltd, and several others across different regions [3] Upcoming Events - Alvotech will participate in the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada, from May 13-15, 2025 [1] - The management team will host one-on-one meetings and participate in a fireside chat on May 14, 2025, from 11:40 am to 12:10 pm EDT [1] - A live audio webcast of the fireside chat will be available to the public, with a recording accessible for 90 days post-event [2]

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the BofA Securities Healthcare Conference 2025, which will be held in Las Vegas, Nevada, May 13-15, 2025. Members of the management team will host one-on-one meetings at the conference. Alvotech will also be participating in a fireside chat on Wednesday, May 14, 2025, at 11:40 am -12:10 pm EDT (15:40-16:10 GMT / 17:40-18:10 CET ...

Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition at the market opening of 320,000 shares in Alvotech at ISK 1,255 per share, by Robert Wessman, Chairman and CEO. ...

Financial Data and Key Metrics Changes - Alvotech raised its full-year revenue guidance for 2025 to $600 million to $700 million and adjusted EBITDA guidance to $200 million to $280 million [7][39] - The company achieved $110 million in product revenues during Q1 2025, an increase of $97 million or 784% compared to the same period in the prior year [30][31] - Adjusted EBITDA for Q1 2025 was $21 million, compared to negative adjusted EBITDA of $38 million for the same period in the prior year [39] Business Line Data and Key Metrics Changes - The Stellara biosimilar was launched in the U.S. market in late February 2025, following successful launches in Europe, Japan, and Canada [8][9] - Alvotech's biosimilar to Humira saw strong uptake in the U.S. market, with a penetration rate of at least 21% by year-end 2024 [20][21] - The company expects to move from two marketed biosimilars to six by early 2026, with three biosimilar filings under review in major markets [11][27] Market Data and Key Metrics Changes - In the U.S. market, Alvotech's Humira biosimilar represented about 12% of total demand for Humira and Humira biosimilars in 2024 [19][21] - The European Stellara market expanded by 9% year-over-year due to the entry of biosimilars, with Alvotech aiming for a double-digit market share by the end of 2025 [23] - Alvotech is the only developer to launch a Stellara biosimilar in Japan, indicating a strong competitive position in that market [24] Company Strategy and Development Direction - Alvotech plans to significantly increase the pace of development, moving four to six new biosimilar candidates into in-house process development each year [12] - The company is focused on a B2B model, which allows it to address a global patient population through 20 strategic commercial partnerships across 90 markets [12] - Alvotech aims to maintain a focus on quality and reliability rather than sacrificing value for market share in a competitive environment [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the Stellara biosimilar in the U.S. market, especially after receiving the interchangeable designation [45] - The company anticipates that if tariffs on pharmaceuticals are applied, they will not disrupt operations or competitiveness in the U.S. market [13] - Management expects to be free cash flow positive in 2025, marking a significant milestone for the company [40] Other Important Information - Alvotech's net debt stood at $1.058 billion as of March 31, 2025, with expectations of mid-single-digit leverage by year-end [41] - The company closed the period with 301.9 million shares outstanding, including unvested earn-out shares [42] Q&A Session Summary Question: Can you clarify the interchangeable exclusivity and its implications? - Management confirmed the receipt of the interchangeable designation and noted that while some competitors may also obtain it, this designation is expected to drive faster uptake of their product [45][46] Question: What is the impact of stocking on the Stellara biosimilar sales? - Management clarified that the sales figures are driven by timing of orders rather than stocking, as they operate on a B2B model [50][51]

Alvotech (ALVO) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 and thank you for standing by. Welcome to the Alvotech Q1 twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Benedict Stephenson. Please go ahead. Speaker1 Thank you. Welcome to Ab ...